Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Cancer Discov. 2021 Feb 15;11(6):1524–1541. doi: 10.1158/2159-8290.CD-20-0812

Figure 5. Traf3-knockout signature is correlated with better response to ICB.

Figure 5.

(A-D) Traf3 knockout signature is positively correlated with (A) MHC-I expression, (B) intratumoral CTL infiltration, (C) ICB response, and (D) overall survival and progression-free survival in patients treated by anti-PD-1 or combined anti-PD-1 and anti-CTLA-4 in the Gide et al. (71) study in melanoma. (E-H) Traf3 knockout signature is positively correlated with (E) MHC-I expression, (F) intratumoral CTL infiltration, (G) ICB response, and (H) overall survival and progression-free survival in patients treated by anti-PD-1 or combined anti-PD-1 and anti-CTLA-4 in the Mariathasan et al. (72) study in urothelial carcinoma. (I) Traf3 knockout signature is positively correlated with MHC-I expression and cytotoxic T cell infiltration and negatively correlated with survival hazard in most ICB treatment clinical trials.